| ASD | autism spectrum disorder |
| FDA | Food and Drug Administration |
| 5-HT | Serotonin, 5-hydroxytryptamine |
| 5-HTR | 5-HT receptor |
| SSRI | selective serotonin reuptake inhibitor |
| SERT | serotonin transporter |
| CNS | central nervous system |
| 5-HTnR | 5-HTn receptor |
| GPCR | G protein-coupled receptor |
| 8-OH-DPAT | 8-hydroxy-2-(di-n-propylamino)-tetraline |
| PKC | protein kinase C |
| DBS | deep brain stimulation |
| ILPFC | infralimbic prefrontal cortex |
| VPA | valproate, valporic acid |
| DOI | 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane |
| PLC | phospholipase C |
| PLA2 | phospholipase A2 |
| ERK | extracellular signal-regulated kinases |
| PET | positron emission tomography |
| HTR2A | serotonin 2A receptor gene |
| CGI-I | Clinical Global Impressions-Improvement |
| cAMP | cyclic adenosine monophosphate |
| Jab1 | Jun activation domain-binding protein 1 |
| Map1b | microtubule-associated protein |
| AC | adenylyl cyclase |
| SAR | structure-activity relationship |